Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin Repair

This article was originally published in Start Up

Executive Summary

A handful of start-ups hopes to fill the cracks in the fragmented market for skin repair. Their approaches vary widely; British start-up Renovo has a pharmaceutical approach to the prevention of scarring. Reconstructive Technologies believes that the best replacement for skin is skin itself; it has developed a bioreactor that accelerates the growth of autograft skin, with both {in vivo} and {in vitro} systems. Artecel Sciences will use adipose-derived stromal cells in cosmesis and hematopoietic support. Niadyne 's platform of unique formulations of niacin lend themselves to a variety of applications, in cosmeceuticals and in cardiovascular disease.

You may also be interested in...



Advanced Wound Care: The Device Industry's New Billion Dollar Product Market

For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (This article also appeared as "Wound Care: Medtech's New Billion Dollar Product Market," Medtech Insight November/December 2007)

Wound Care: Medtech's New Billion Dollar Product Market

For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (A Reprint of "Advanced Wound Care: The Device Industry's Billion Dollar Product Market," appearing in START-UP, November 2007.

Renovo Ltd.

There are currently no effective pharmacological treatments to prevent scarring following trauma or surgery. Renovo, a spin-off from the University of Manchester, was set up two years ago with this market in mind. Renovo has two anti-scarring compounds in clinical trials, based on Transforming Growth Factor Beta 3, which appears to promote healing without scarring in embryos, and an antagonist of Transforming Growth Factor Beta 1 and Beta 2, growth factors which appear to be associated with scarring in adults.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel